Verastem | VSTM - Net Income


Verastem reported $-8.26M in Net Income for its fiscal quarter ending in June of 2024.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alaunos Therapeutics USD -1.16M 417K Sep/2025
AstraZeneca USD 2.33B 207M Dec/2025
Curis USD -11.8M 80K Jun/2024
Cytokinetics USD -183.03M 123.15M Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Laboratory Of America USD 164.7M 96.4M Dec/2025
Novartis USD 3.93B 96M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
TG Therapeutics USD 23.04M 367.86M Dec/2025
Verastem USD -8.26M 25.61M Jun/2024